CYP2E1 and non-small cell lung carcinoma: Conversely other studies showednon-significant impact of CYP1A1*2C, CYP1B1*4, CYP2D6*1A, CYP2E1*6, CYP2E1*7B polymorphisms with both platinum and taxane basedchemotherapy response in in non-small cell lung carcinoma patients (CLC-P) [15,17, 34].